AIDS Malignancy Clinical Trials Consortium (Limited Competition U01) | Apply Online

Opportunity Summary:

The AIDS Malignancy Clinical Trials Consortium (Limited Competition U01) grant opportunity (RFA-CA-10-502) was a National Institutes of Health (NIH) cooperative agreement intended to continue and strengthen the work of the AIDS Malignancy Consortium (AMC), a clinical trials network focused on cancers that occur in people living with HIV. The central aim was to support a coordinated, multi-site program that could design and run clinical studies that directly improve prevention and treatment of HIV-associated malignancies, while also using those trials as a platform to learn more about the underlying biology of these cancers. In practice, the FOA was built to maintain a standing infrastructure capable of launching and completing clinical trials efficiently across multiple participating institutions, rather than funding a single stand-alone study.

The FOA laid out five major program goals. First, it emphasized the design, development, and evaluation of clinical interventions for prevention and treatment of malignancies in patients with HIV infection, meaning the network would be expected to propose and carry out interventional trials that test therapies, supportive care strategies, or prevention approaches relevant to HIV-positive populations. Second, it prioritized improving clinical management and therapeutics for HIV-associated malignancies, reflecting the need to refine treatment strategies in a population that may have unique immune status considerations, drug-drug interaction risks, and comorbidity profiles. Third, it called for investigation of the biology of HIV-related malignancies within the context of clinical trials, which points to embedding translational and correlative science alongside patient enrollment and treatment, such as tumor profiling, viral or immune biomarkers, and mechanisms of treatment response or resistance. Fourth, it highlighted management of issues of international importance in HIV-associated malignancies, signaling that the consortium was expected to address global or cross-border needs, including research questions relevant to regions with high HIV burden and potentially different cancer epidemiology or resource constraints. Fifth, it required distribution of excess tumor tissue and other relevant biologic fluids to the AIDS and Cancer Specimen Resource (ACSR), ensuring that valuable biospecimens collected through AMC trials would be shared for future or ongoing research, increasing the scientific return beyond the original protocols.

Structurally, the award was designed to support a networked clinical trials enterprise through subcontracts for multiple functional components. These included a coordinating center to manage network operations and study implementation, core clinical sites and affiliate sites to enroll participants and deliver protocol-driven care, network laboratories to support specialized testing and correlative assays, and a statistical center to provide trial design expertise, data management oversight, and analysis. The FOA also specified that sites would receive patient care costs on a capitation basis, meaning funding tied to participant accrual and trial activity, and that support would also cover laboratory correlative studies, clinical pharmacology work, and international study components. This reflects the expectation that the consortium would not only treat and follow participants, but also generate high-quality clinical and biological datasets that can answer mechanistic and therapeutic questions.

From a scientific organization standpoint, the consortium was expected to operate with at least four disease-oriented working groups: Kaposi sarcoma (KS), lymphoma, HPV-associated cancers, and non-AIDS-defining cancers (NADCs). This working-group model is typical of large networks because it creates focused teams responsible for developing concepts, prioritizing trial ideas, and ensuring that protocols align with the most pressing clinical needs and emerging science in each disease area. The inclusion of both classic AIDS-defining malignancies (like KS and certain lymphomas) and NADCs reflects the reality that, as HIV care improved, cancer patterns in people living with HIV broadened, creating a need for trials beyond the historically dominant AIDS-defining cancers.

The funding mechanism was a U01 cooperative agreement, which is distinct from a standard research project grant because NIH program staff typically have substantial involvement in the oversight and direction of the funded activities. Cooperative agreements are often used for clinical trials networks where coordination, standardization, and shared governance between NIH and the awardee are important for meeting network-wide milestones, maintaining quality control, and ensuring timely trial execution.

In terms of money and expected awards, NIH anticipated making one award under this FOA, with approximately $4.68 million available for year one. There was no cost sharing or matching requirement. The opportunity was categorized under discretionary funding and aligned with multiple cancer-related CFDA program areas, spanning prevention, detection/diagnosis, treatment, biology, and control, which underscores that the consortium was expected to contribute across the full continuum of cancer research rather than focusing narrowly on a single domain.

Eligibility was highly restricted because this was a limited competition FOA. Only the current AMC Group Chair recipient institution (associated with award U01CA121947) was eligible to apply. While the general eligible applicant category included public and state-controlled institutions of higher education, the practical reality is that only the incumbent lead institution for the AMC could submit an application, consistent with the FOA goal of continuing an established consortium rather than creating a new one.

Key dates show that the FOA was posted on December 24, 2009, with an application deadline of March 3, 2010, and an archive date of April 3, 2010. The sponsoring agency was NIH, and the full announcement was made available through the NIH grants guide. Overall, the opportunity was essentially a continuation and formal reauthorization of the AMC infrastructure, designed to keep a specialized HIV-cancer clinical trials network operating at scale, with integrated translational research and biospecimen sharing, and with the capacity to address both domestic and international research priorities in HIV-associated malignancies.

Browse more opportunities from the same agency: National Institutes of Health

Browse more opportunities from the same category: Education Health

Next opportunity: RECOVERY PACIFIC CREST TRAIL MAINTENANCE AND TRAILHEAD CONSTRUCTION AND TRAIL MAINTENANCE IN THE TURTLE MOUNTAINS WILDERNESS

Previous opportunity: Alliances for Broadening Participation in STEM

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for RFA CA 10 502

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (RFA CA 10 502) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "RFA CA 10 502", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.